CONNECT 1903
A Pilot and Surgical Study of Larotrectinib for Treatment of Children with Newly-Diagnosed High-Grade Glioma with NTRK Fusion
Brain and other Central Nervous System (CNS) Tumours
Recent research shows that a new oral tablet drug, larotrectinib, has produced promising results by shrinking some solid tumours that have an abnormal or mutated NTRK gene in adults and children.
High grade gliomas (HGG) are fast growing, aggressive brain cancers and if they recur after initial treatment, there are no effective treatment options. This study will investigate if larotrectinib alone as well as Larotrectinib in combination with chemotherapy or radiotherapy can be of benefit in children with high grade gliomas with the mutated NTRK gene. This international trial will study how well the drug is tolerated and its effectiveness to shrink these tumours when used alone or when given with standard chemotherapy or after radiation.
Disease stage: Newly diagnosed
Patient age range: birth to 21 years of age
Trial sponsors:
- National: ANZCHOG
- International: Collaborative Network for Neuro-oncology Clinical Trials (CONNECT)
Sites
Perth Children’s Hospital
Queensland Children’s Hospital
Sydney Children’s Hospital
